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Persistent Comorbid Symptoms of Depression and Anxiety Predict
Mortality in Heart Disease
Abstract
Background
Incident anxiety and depression are associated separately with cardiac events and mortality in patients after
acute coronary syndromes, but the influence of persistent comorbid depression and anxiety on mortality
remains unknown. The purpose of this study was to determine the prevalence of comorbid persistent
depressive and anxious symptoms in individuals with ischemic heart disease and to evaluate effects on
mortality.
Methods
Prospective, longitudinal cohort design in the context of a randomized trial to decrease patient delay in
seeking treatment for ischemic heart symptoms (PROMOTION trial) was used, with twelve-month follow-
up of 2325 individuals with stable ischemic heart disease. Participants were assessed on enrollment and at 3
months using the Multiple Adjective Affect Checklist and the Brief Symptom Inventory for depressive and
anxious symptoms, respectively.
Results
At 3 months, 608 individuals (61.7%) reported persistent symptoms of depression, anxiety, or both. Three
hundred seventy-nine (42.5%) and 1056 (45.4%) had persistent anxious and depressive symptoms,
respectively. Those with persistent, comorbid symptoms had higher mortality compared to others (p = .029).
The combined presence of anxious and depressive symptoms contributed significantly to mortality when
compared to symptom-free participants (OR 2.35, 95% CI 1.23–4.47, p = .010). The presence of persistent
depressive symptoms only and persistent anxious symptoms only were not associated with death, when other
demographic and clinical variables were considered.
Conclusions
Persistent symptoms of anxiety and depression increased substantially the risk of death in patients with
ischemic heart disease. Future research into shared and unique pathways and treatments is needed.
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Abstract
Background—Incident anxiety and depression are associated separately with cardiac events and
mortality in patients after acute coronary syndromes, but the influence of persistent comorbid
depression and anxiety on mortality remains unknown. The purpose of this study was to determine
the prevalence of comorbid persistent depressive and anxious symptoms in individuals with
ischemic heart disease and to evaluate effects on mortality.
Methods—Prospective, longitudinal cohort design in the context of a randomized trial to
decrease patient delay in seeking treatment for ischemic heart symptoms (PROMOTION trial) was
used, with twelve-month follow-up of 2325 individuals with stable ischemic heart disease.
Participants were assessed on enrollment and at three months using the Multiple Adjective Affect
Checklist and the Brief Symptom Inventory for depressive and anxious symptoms, respectively.
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Results—At three months, 608 individuals (61.7%) reported persistent symptoms of depression,
anxiety, or both. Three hundred seventy-nine (42.5%) and 1056 (45.4%) had persistent anxious
and depressive symptoms, respectively. Those with persistent, comorbid symptoms had higher
mortality compared to others (p = .029). The combined presence of anxious and depressive
symptoms contributed significantly to mortality when compared to symptom-free participants (OR
2.35, 95% CI 1.23 – 4.47, p = .010). The presence of persistent depressive symptoms only and
persistent anxious symptoms only were not associated with death, when other demographic and
clinical variables were considered.
Conclusions—Persistent symptoms of anxiety and depression increased substantially the risk of
death in patients with ischemic heart disease. Future research into shared and unique pathways and
treatments is needed.
Keywords
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Introduction
Depression and anxiety are common in patients with chronic ischemic heart disease (IHD).
For depression and anxiety, prevalence rates of 32% and 26%, respectively, have been
reported in post-myocardial infarction patients and in stable populations of IHD patients.[1–
5] These emotional states are known to persist after a cardiac event, and rates of both have
been reported to increase during the first year after a myocardial infarction (MI).[3] In IHD
patients, depression has been associated independently with increased mortality and
morbidity, including increased cardiac and all-cause mortality and increased non-fatal
cardiac events.[6–10] While anxiety is also associated with increased morbidity in IHD, its
association with mortality is less certain.[11,12]
Despite the known deleterious effects of both incident depression and anxiety on cardiac
outcomes, the impact of persistent mood disorders has received relatively little attention.
Persistent depression has been associated with poor adherence to treatment regimens after
MI, but few studies have looked at the effect of persistent depression on cardiac events or
mortality. A recent report regarding persistent depression in men with Type 2 diabetes found
that persistent depression was associated with lower mortality risk. Evidence regarding the
effect of persistent anxiety on cardiac prognosis is also scarce.[12] Both persistent anxiety
and depression have been shown to have negative effects on subsequent health-related
quality of life.[13]
Anxiety and depression are highly comorbid, both in psychiatric populations and in
individuals with chronic medical conditions, including heart disease.[14–16] Although the
effect of depression on future cardiac events has been well established, previous reports
have not considered the mediating or confounding effect of co-existing anxiety on mortality
and morbidity. Anxiety and depression may act synergistically to increase the risk of death
or other cardiac events. To date, this possibility has not been systematically investigated.
Only a single study has reported that anxiety is more closely related to cardiac events than
depression, when both are present in patients with IHD.[17] No investigators have reported
the influence of comorbid persistent anxiety and persistent depression on subsequent cardiac
events. The purpose of the current study was to determine the prevalence of comorbid
persistent depression and anxiety in community dwelling individuals with documented IHD
and to evaluate the effect of comorbid persistent depression and anxiety on mortality.
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Materials and Methods
Design
As part of a large multicenter clinical trial to reduce prehospital delay in IHD patients
experiencing symptoms of acute coronary syndrome (the PROMOTION trial), 3523 patients
from seven sites in three countries (United States, Australia, New Zealand) were randomized
to received either usual care or a brief teaching intervention delivered by expert nurses and
aimed at increasing knowledge of acute coronary event symptoms, along with when and
how to seek treatment.[18] This report constitutes an a priori planned analysis of the
PROMOTION trial.
Sample
After approval of internal review boards at each site, patients gave informed consent prior to
study participation. Patients were eligible for the PROMOTION trial if they had a diagnosis
of IHD, confirmed by their physician and/or medical record, and lived independently (i.e.,
not in an institutional setting). Patients were excluded if they have any of the following: 1) a
complicating serious comorbidity (including psychiatric diagnoses of current psychosis or
bipolar disorder), 2) untreated malignancy or neurological disorder which impaired
cognition, 3) inability to understand spoken English and unable to respond to English
language questions on the data collection instruments, and 4) a major and uncorrected
hearing loss. To avoid selection bias, individuals with previous histories of mood disorders
were not excluded. Of the 3523 patients enrolled in the parent study, 2325 had complete data
at all time points and were included in the current report.
Instruments
Two self-report instruments were used to measure depression and anxiety. Depression was
measured by the depression subscale of the Multiple Adjective Affect Checklist (MAACL-
D), a self-report measure consisting of 132 alphabetically arranged adjectives. Higher scores
indicate greater depressive symptoms. The MAACL-D has been used extensively in
research and clinical practice and has established reliability and validity, with reported
internal consistency reported to be 0.89, .83, and .88.[19,20] In the current study, the
Cronbach’s α coefficients was 0.86. Anxiety was measured using the anxiety subscale of the
Brief Symptom Inventory. It consists of 6-items that are rated by the patient on a 5-point
scale (0–4) of distress ranging from "not at all" to "extremely". Item scores are summed and
the mean obtained. The range of scores is 0 to 4, with higher scores indicating higher levels
of anxiety symptoms. Construct, convergent, discriminant, and predictive validity of the
Brief Symptom Inventory have been demonstrated in a series of studies.[21] In this study,
reliability of the instrument was demonstrated by a Cronbach’s alpha of 0.86. Demographic
and clinical data were obtained by self-report and confirmed by medical record review.
Procedure
After giving informed consent, individuals completed the study instruments and were
randomized to either the intervention or treatment group of the parent study.[18] At three
months, participants repeated the MAACL and the BSI. Those patients who scored higher
than reported community norms established for each instrument (BSI > 0.33[21] or
MAACL-D >11[19]) both at baseline and at 3 months were considered to have persistent
symptoms of anxiety and/or depression. At three, 12, and 24 months, they were queried
regarding occurrence of acute coronary events and emergency room visits. Medical records
were obtained to confirm all events. Patients were followed for up to a median of 21.6
months. Cardiac and all-cause deaths were verified from medical records and death
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certificates. Medical records were reviewed by trained researchers unaware of participants’
level of anxiety or depression symptoms.
Analysis
Measures of central tendency were used to describe the sample. Patients identified as
consistently having symptoms of both anxiety and depression were compared to all others
by t-test for continuous variables and Chi-square for categorical data. The effect of
persistent symptoms of both anxiety and depression on all-cause mortality was evaluated
using a multivariable Cox regression model. Demographic and clinical variables that were
significantly different in individuals with and without persistent anxiety and depression at
the ≤ .10 level were included in the model. Demographics (age, gender, education, marital
status) and clinical (comorbidities, risk factors, prior cardiac procedures) variables were
entered into the model first as separate blocks. Group assignment (intervention or control) in
the parent study was entered in an individual block, prior to the entry of a variable coding
the presence/absence of persistent anxiety and persistent depression as a final block in the
model. Forced entry was used for all variables. Data were analyzed using SPSS 16.0
(Chicago, IL).
Results
Patients were primarily male (n = 1717, 73.8%) and elderly (67.2 ± 10.7 years). Persistent
symptoms of both anxiety and depression were common in the sample. Overall, 1435
individuals (61.7%) reported persistent symptoms of anxiety, depression or both (Figure 1).
Considering symptoms of each dysphoria individually, 987 (42.5%) participants had
persistent symptoms of anxiety, while 1056 (45.4%) had persistent depressive symptoms.
Demographic and clinical characteristics of patients with and without comorbid persistent
symptoms of anxiety and depression are summarized in Table 1. Regarding demographic
characteristics, patients with both persistent symptoms of both anxiety and depression were
more likely to be female and poorer than all others. A higher proportion of women reported
the presence of both symptoms than did men (221 [30.6%] vs. 387 [24.2%], p = .001). They
were younger (65.8 ± 11.4) than those with either symptoms of anxiety only, symptoms of
depression only or neither (67.5 ± 9.77, p = .013). Clinical factors that distinguished
individuals with persistent symptoms of both anxiety and depression from all others were:
angina (p = .025), myocardial infarction (p = .028), and diabetes (p = .006); current smoking
(p = .010), being sedentary (p < .001); and lack of participation in cardiac rehabilitation (p
= .010).
Over the follow-up period, a total of 63 participants died. Twenty-three (36.5%) deaths were
attributable to cardiac causes. The frequency of deaths differed across the four groups (p = .
029), with the greatest proportion occurring in individuals with both persistent symptoms of
both anxiety and depression (Figure 2). Of those with symptoms of both anxiety and
depression, 23 of 608 individuals (3.78%) died over 12 months of follow-up, compared to
17 of 890 individuals (1.87%) in the group without symptoms (p = .010, see Figure 3).
The relationship of anxiety and depression symptom status to mortality when relevant
demographic and clinical variables are considered is presented in Table 2. The presence of
symptoms of comorbid anxiety and depression, but not the presence of only anxiety
symptoms or only depressive symptoms, was significantly associated with mortality (Hazard
Ratio = 2.35, 95% confidence interval [CI] 1.23 – 4.47, p = .010). In addition to the presence
of comorbid symptoms of anxiety and depression, only age (Harzard Ratio, = 1.08, 95% CI
= 1.04 – 1.11, p < .001) and history of myocardial infarction (Hazard Ratio = 1.985, 95% CI
1.14 – 3.45, p = .015) were significant predictors of mortality. For every added year of age,
there as an up to 11% increased risk of mortality. Compared to participants who had not had
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myocardial infarctions, those with a prior history of infarction were 3.5 times more likely to
die during the study period. Other factors that were significant when considered alone, such
as being female, past medical history, smoking status, activity level, and cardiac rehab
attendance, did not contribute independently to mortality risk in the multivariate analysis.
Discussion
Our findings emphasize the ubiquitousness of symptoms of anxiety and depression in
community-dwelling adults with IHD. The majority of individuals in our study (61.2%)
suffered from significant symptoms of depression, anxiety or both. This is consistent with
the reports of other investigators, who confirm that persons with IHD are more likely to
experience both anxiety and depression than those without IHD.[22–24] In fact, among
individuals with IHD, the odds of developing anxiety and depression are double those of
individuals without heart disease, even after adjusting for age and gender. [25] Both anxiety
and depression are known to be associated with poorer outcomes in patients with IHD,
which underscores the importance of our findings. In fact, the American Heart Association
has issued a consensus statement recently endorsing the need for routine depression
screening in all patients with IHD.{Lichtman, 2008 741 /id}
This report is one of only a few which have investigated the combined effects of symptoms
of both anxiety and depression on cardiac outcomes in those with identified IHD. In
evaluating the long-term effects of multiple psychological risk factors, Frasure-Smith and
colleagues found that only anxiety and depression (compared to anger, stress and social
support) were associated with cardiac mortality.[27] By using a single instrument (the
General Health Questionnaire-20) that evaluated psychological distress as a combination of
symptoms of depression, anxiety, and dysfunction, they found an association of comorbid
anxiety and depression with 5-year cardiac mortality. However, in models adjusted for
disease severity, age, and risk factors, only depression conferred an increased risk of cardiac
death. In a second report evaluating cardiac mortality plus acute cardiac events, Frasure-
Smith et al compared the effect of comorbid anxiety and depression to that of a single
diagnosis (anxiety or depression) on occurrence of cardiac events (including mortality, acute
coronary syndrome or nonelective revascularization) over two years of follow-up.[28] They
found no added effect for the comorbid conditions, compared to single conditions.
Differences in the Frasure-Smith reports compared to our findings may be attributed to how
and when IHD sufferers were enrolled, how and when mood disorders were measured, and
to the selection of outcome variables. We focused on community-dwelling individuals with
IHD, while Frasure-Smith et al enrolled only individuals hospitalized for acute coronary
syndrome (ACS). Thus, at enrollment our sample may have been more heterogeneous, but
with fewer patients in an acute phase of their cardiac illness. While the Frasure-Smith group
included only cardiac mortality and other cardiac-related events, we used a broader category
of all-cause mortality, which was more appropriate for our older, community-dwelling
sample.[29,30] Finally, we measured symptoms of anxiety and depression at baseline and
again at three months to evaluate persistence of symptoms, while the earlier reports used
only baseline assessments.
This study is unique in its focus on the relationship of persistent comorbid symptoms of
anxiety and depression to mortality in IHD patients. A few studies have examined separately
the persistence of anxiety or depression on outcomes in cardiac or other populations, with
equivocal findings. Grace et al reported that persistent anxiety (six months) was associated
with a greater number of self-reported recurrent cardiac events, after controlling for IHD
severity and smoking, in the first year after ACS.[31] Similarly, Rieckmann et al reported
that ACS patients who were persistently depressed (three months) were markedly more
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likely to be non-adherent to electronically monitored aspirin therapy than nondepressed
individuals or those with remitted depression.[32] Conversely, in a large sample of veterans
with Type 2 diabetes, Richardson et al reported that even though 10-year all-cause mortality
was greater in those with depression, the odds of death decreased more in whites with
persistent depression than in blacks.[33] Persistent depression, assessed at 18 month
intervals over six years, has been reported to occur more frequently in older women than in
older men.[34] While we controlled for gender in our analysis, our sample was too
homogeneous to consider racial differences. Race and gender interactions with persistent
anxiety and depression require further study.
Our use of all-cause mortality, rather than only cardiac-related mortality, as an outcome
measure extends initial evidence that persistent symptoms of depression predict later
physical health status in IHD patients.[35] It is likely to also to be a more inclusive measure
of adverse outcome and less susceptible to bias in coding. These findings are consistent with
previous reports that found incident depression to be an independent predictor of all-cause
mortality.[36] Several proposed mechanisms point to the relationship we found between
persistently comorbid symptoms of anxiety and depression and all-cause mortality. In
addition to the pathways hypothesized above to account for the added effect of comorbid
symptoms of anxiety and depression on survival, additional factors may explain why these
conditions are related not only to cardiac death, but to all causes of death. First, depression
and anxiety may exacerbate other common medical conditions, such as diabetes, stroke, and
hypertension, in which depression has been implicated as a predictor of disease-specific
mortality.[37,38] Second, both anxiety and depression may affect cognitive performance and
behavior in the course of chronic conditions, thereby increasing disability and mortality.
[29,39] Third, depression appears to have an independent effect (after controlling for
chronic conditions) on total life expectancy, particularly in those aged > 70 years, who
accounted for 43% of our sample.[30]. Finally, both anxiety and depression are associated
with lower quality of life and lower health status, which may in turn, be related to mortality.
[40,41]
Several biobehavioral pathways may account for our findings. Both anxiety and depression
may activate stress mechanisms that increase oxygen consumption and potentiate
myocardial ischemia.[39] Each condition is believed to activate separate autonomic and
adrenal pathways that lead to increased sudden death (anxiety) or increased coaguability and
risk of thrombosis (depression).[39,42–44] In addition, investigators hypothesize that both
anxiety and depression may reduce quality of life and contribute to adverse health behaviors,
such as inactivity, smoking, and lack of attention to dietary restrictions and medication
adherence, which exacerbate atherosclerosis.[43,44]. Regarding depression, new reports
suggest that behavioral, rather than biologic, mediators, may be more important in
explaining the its relationship to mortality in cardiac patients.[45] Irrespective of
mechanisms, there is compelling evidence that depression and anxiety are linked to cardiac
disease; both are highly prevalent, but underrecognized in cardiac patients.{Rumsfeld, 2005
742 /id}
Our study has several limitations. We used self-report instruments to determine the presence
of symptoms anxiety and depression, rather than diagnostic interviews or identification of
clinical syndromes. However, substantial evidence now supports the belief that symptoms of
depression and anxiety alone confer greater risk of poor health outcomes and that clinical
depression and depressive symptoms share a large proportion of common variance.[36,47]
Also, use of self-report may have introduced recall bias. We included only subjects in whom
we could confirm potential confounding variables, so selection bias may have been possible.
However, we found no differences in subjects who were included in the analysis and those
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who were not. Our sample was largely Caucasian, so we could not consider race or ethnicity
as a covariate.
Our findings have implications for both clinical practice and research. Given the extremely
common nature of anxious and depressive symptoms found in our study, clinicians must be
assess patients periodically for both these conditions. While it is important to identify and
treat new depressive or anxious symptoms, it may be even more important to attend to
persistent symptoms and to reassess treatment plans if symptoms do not remit over time.
Current evidence indicates that psychotherapy combined with pharmacotherapy is often the
most effective treatment for clinical depression and anxiety, that treatment is most
successful when priority is placed on patient preferences, and that treatment offered in a
primary care setting rather than a psychiatric one, may increase adherence.[48,49] Future
research should aim at evaluating strategies to optimize successful screening and treatment,
integrate assessment and treatment into clinical practice, and make treatment options more
acceptable to IHD patients. In addition, more studies are needed to explicate shared and
unique biobehavioral mechanisms that link anxiety and depression to mortality in the
context of IHD. Finally, further study is needed to identify subgroups of IHD patients, such
as older adults, women, and specific racial or ethnic groups, in whom anxiety, depression or
both confer the greatest risk of early death.
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Figure 1.
Distribution of Symptom Groups (Anxious, Depressive, Both, Neither)
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Figure 2.
Frequency of Death by Symptom Group (Anxious, Depressive, Both, Neither). Black =
deaths; Stripped = survivors; White = total
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Figure 3.
Hazard Plot of Symptoms Groups (Anxious, Depressive, Both, Neither) on Morality (N =
2325)
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Table 1
Demographic and Clinical Characteristics
Variable Total Sample
(n = 2325)
n (%)
Persistent Anxious and
Depressive Symptoms
(n = 608)
n (%)
All Others
(n = 1717)
n (%)
P
Age: .001
< 56 years 380 (16.3) 128 (21.1) 252 (14.7)
56 – 64.9 years 524 (22.5) 143 (23.5) 381 (22.2)
65 – 79.9 years 1178 (50.7) 274 (45.1) 904 (52.6)
≥ 80 years 243 (10.5) 63 (10.4) 180 (10.5)
Female 723 (31.1) 221 (36.3) 502 (29.2) .001
Married 1664 (71.6) 419 (68.9) 1245 (72.5) .094
Uninsured or government only 1178 (50.8) 318 (52.4) 289 (47.6) .370
Not Caucasian 177 (7.6) 54 (8.9) 123 (7.2) .182
Income in U.S. dollars: .001
< $15K 515 (22.2) 169 (27.8) 346 (20.2)
$15 – 30K 556 (23.9) 141 (23.2) 415 (24.2)
$30 – 45K 403 (17.3) 109 (17.9) 294 (17.1)
$45 – 60K 327 (14.1) 66 (10.9) 261 (15.2)
> $60K 524 (22.5) 123 (20.2) 401 (23.4)
Angina 1426 (61.3) 396 (65.1) 1030 (60.0) .026
Myocardial infarction 1288 (55.4) 360 (59.2) 928 (54.0) .029
PTCA 1121 (48.2) 308 (50.7) 813 (47.4) .171
Stent 933 (40.4) 254 (41.9) 679 (39.8) .362
Bypass surgery 1083 (46.6) 279 (45.9) 804 (46.8) .705
Peripheral artery disease 230 (9.9) 65 (10.7) 165 (9.6) .431
Diabetes 475 (20.4) 152 (25.0) 323 (18.8) .002
Stroke 216 (9.3) 68 (11.2) 148 (8.6) .073
Current smoker 128 (5.5) 46 (7.6) 82 (4.8) .013
Sedentary 716 (30.8) 223 (36.7) 493 (28.7) <.001
Attended cardiac rehab 1267 (54.5) 304 (50.0) 963 (56.1) .010
Assigned to experimental group 1172 (50.4) 288 (47.4) 884 (51.5) .080
Alive at 12 months follow-up 2262 (97.3) 585 (96.2) 1677 (97.7) .058
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